|
1
|
Parkin DM: Global cancer statistics in the
year 2000. Lancet Oncol. 2:533–543. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yamazaki H, Oshima A, Murakami R, Endoh S
and Ubukata T: A long-term follow-up study of patients with gastric
cancer detected by mass screening. Cancer. 63:613–617. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY
and Shen KH: Peritoneal carcinomatosis and lymph node metastasis
are prognostic indicators in patients with Borrmann type IV gastric
carcinoma. Hepatogastroenterology. 49:874–877. 2002.PubMed/NCBI
|
|
4
|
Sadeghi B, Arvieux C, Glehen O, Beaujard
AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL,
Faure JL, et al: Peritoneal carcinomatosis from non-gynecologic
malignancies: Results of the EVOCAPE 1 multicentric prospective
study. Cancer. 88:358–363. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fushida S, Kinoshita J, Yagi Y, Funaki H,
Kinami S, Ninomiya I, Fujimura T, Nishimura G, Kayahara M and Ohta
T: Dual anti-cancer effects of weekly intraperitoneal docetaxel in
treatment of advanced gastric cancer patients with peritoneal
carcinomatosis: A feasibility and pharmacokinetic study. Oncol Rep.
19:1305–1310. 2008.PubMed/NCBI
|
|
6
|
Shirao K, Boku N, Yamada Y, Yamaguchi K,
Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A, et al:
Gastrointestinal Oncology Study Group of the Japan Clinical
Oncology Group: Randomized Phase III study of 5-fluorouracil
continuous infusion vs. sequential methotrexate and 5-fluorouracil
therapy in far advanced gastric cancer with peritoneal metastasis
(JCOG0106). Jpn J Clin Oncol. 43:972–980. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fushida S, Kinoshita J, Kaji M, Hirono Y,
Goda F, Yagi Y, Oyama K, Sudo Y, Watanabe Y and Fujimura T: Society
for Study of Peritoneal Carcinomatosis in Gastric Cancer: Phase
I/II study of intraperitoneal docetaxel plus S-1 for the gastric
cancer patients with peritoneal carcinomatosis. Cancer Chemother
Pharmacol. 71:1265–1272. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fushida S, Oyama K, Kinoshita J, Tsukada
T, Okamoto K, Tajima H, Ninomiya I, Kitagawa H, Fujimura T and Ohta
T: Intraperitoneal chemotherapy as a multimodal treatment for
gastric cancer patients with peritoneal metastasis. J Cancer Ther.
4:6–15. 2013. View Article : Google Scholar
|
|
9
|
Kalluri R and Zeisberg M: Fibroblasts in
cancer. Nat Rev Cancer. 6:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tlsty TD: Stromal cells can contribute
oncogenic signals. Semin Cancer Biol. 11:97–104. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zeisberg EM, Potenta S, Xie L, Zeisberg M
and Kalluri R: Discovery of endothelial to mesenchymal transition
as a source for carcinoma-associated fibroblasts. Cancer Res.
67:10123–10128. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pietras K and Ostman A: Hallmarks of
cancer: Interactions with the tumor stroma. Exp Cell Res.
316:1324–1331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lewis CE and Pollard JW: Distinct role of
macrophages in different tumor microenvironments. Cancer Res.
66:605–612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Komohara Y, Ohnishi K, Kuratsu J and
Takeya M: Possible involvement of the M2 anti-inflammatory
macrophage phenotype in growth of human gliomas. J Pathol.
216:15–24. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Niino D, Komohara Y, Murayama T, Aoki R,
Kimura Y, Hashikawa K, Kiyasu J, Takeuchi M, Suefuji N, Sugita Y,
et al: Ratio of M2 macrophage expression is closely associated with
poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL).
Pathol Int. 60:278–283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hasita H, Komohara Y, Okabe H, Masuda T,
Ohnishi K, Lei XF, Beppu T, Baba H and Takeya M: Significance of
alternatively activated macrophages in patients with intrahepatic
cholangiocarcinoma. Cancer Sci. 101:1913–1919. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ishigami S, Natsugoe S, Tokuda K, Nakajo
A, Okumura H, Matsumoto M, Miyazono F, Hokita S and Aikou T:
Tumor-associated macrophage (TAM) infiltration in gastric cancer.
Anticancer Res. 23:4079–4083. 2003.PubMed/NCBI
|
|
19
|
Yamaguchi T, Fushida S, Yamamoto Y,
Tsukada T, Kinoshita J, Oyama K, Miyashita T, Tajima H, Ninomiya I,
Munesue S, et al: Tumor-associated macrophages of the M2 phenotype
contribute to progression in gastric cancer with peritoneal
dissemination. Gastric Cancer. 19:1052–1065. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Donaldson KL, Goolsby GL, Kiener PA and
Wahl AF: Activation of p34cdc2 coincident with
taxol-induced apoptosis. Cell Growth Differ. 5:1041–1050.
1994.PubMed/NCBI
|
|
21
|
Gelmon K: The taxoids: Paclitaxel and
docetaxel. Lancet. 344:1267–1272. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Noda K, Ikeda M, Kudo R, Nishiya I, Yajima
A, Tanaka K, Kodama S, Takahashi T, Tokunaga A, Satoh I, et al:
Phase II study of paclitaxel (BMS-181339) in patients with ovarian
cancer by 3-hour intravenous infusion. Gan To Kagaku Ryoho.
23:317–325. 1996.(In Japanese). PubMed/NCBI
|
|
23
|
Furuse K, Naka N, Takada M, Kinuwaki E,
Kudo S, Takada Y, Yamakido M, Yamamoto H and Fukuoka M; West Japan
Lung Cancer Group, : Phase II study of 3-hour infusion of
paclitaxel in patients with previously untreated stage III and IV
non-small cell lung cancer. Oncology. 54:298–303. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ito Y, Horikoshi N, Watanabe T, Sasaki Y,
Tominaga T, Okawa T, Tabei T, Kuraishi Y, Tamura K, Abe R, et al:
Phase II study of paclitaxel (BMS-181339) intravenously infused
over 3 hours for advanced or metastatic breast cancer in Japan.
BMS-181339 Breast Cancer Study Group. Invest New Drugs. 16:183–190.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishigami H, Kitayama J, Kaisaki S,
Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita
H, et al: Phase II study of weekly intravenous and intraperitoneal
paclitaxel combined with S-1 for advanced gastric cancer with
peritoneal metastasis. Ann Oncol. 21:67–70. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsukada T, Fushida S, Harada S, Terai S,
Yagi Y, Kinoshita J, Oyama K, Tajima H, Ninomiya I, Fujimura T, et
al: Low-dose paclitaxel modulates tumour fibrosis in gastric
cancer. Int J Oncol. 42:1167–1174. 2013.PubMed/NCBI
|
|
27
|
Jordan MA, Toso RJ, Thrower D and Wilson
L: Mechanism of mitotic block and inhibition of cell proliferation
by taxol at low concentrations. Proc Natl Acad Sci USA. 90:pp.
9552–9556. 1993; View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Axel DI, Kunert W, Göggelmann C, Oberhoff
M, Herdeg C, Küttner A, Wild DH, Brehm BR, Riessen R, Köveker G, et
al: Paclitaxel inhibits arterial smooth muscle cell proliferation
and migration in vitro and in vivo using local drug delivery.
Circulation. 96:636–645. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Colombo A, Drzewiecki J, Banning A, Grube
E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, et
al: TAXUS II Study Group: Randomized study to assess the
effectiveness of slow- and moderate-release polymer-based
paclitaxel-eluting stents for coronary artery lesions. Circulation.
108:788–794. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma Y, Shurin GV, Gutkin DW and Shurin MR:
Tumor associated regulatory dendritic cells. Semin Cancer Biol.
22:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sevko A, Michels T, Vrohlings M, Umansky
L, Beckhove P, Kato M, Shurin GV, Shurin MR and Umansky V:
Antitumor effect of paclitaxel is mediated by inhibition of
myeloid-derived suppressor cells and chronic inflammation in the
spontaneous melanoma model. J Immunol. 190:2464–2471. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kawasaki K, Akashi S, Shimazu R, Yoshida
T, Miyake K and Nishijima M: Mouse toll-like receptor 4.MD-2
complex mediates lipopolysaccharide-mimetic signal transduction by
Taxol. J Biol Chem. 275:2251–2254. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sica A and Mantovani A: Macrophage
plasticity and polarization: In vivo veritas. J Clin Invest.
122:787–795. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jaguin M, Houlbert N, Fardel O and
Lecureur V: Polarization profiles of human M-CSF-generated
macrophages and comparison of M1-markers in classically activated
macrophages from GM-CSF and M-CSF origin. Cell Immunol. 281:51–61.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kobayashi M, Sakamoto J, Namikawa T,
Okamoto K, Okabayashi T, Ichikawa K and Araki K: Pharmacokinetic
study of paclitaxel in malignant ascites from advanced gastric
cancer patients. World J Gastroenterol. 12:1412–1415. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sica A and Bronte V: Altered macrophage
differentiation and immune dysfunction in tumor development. J Clin
Invest. 117:1155–1166. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Weigert A, Sekar D and Brüne B:
Tumor-associated macrophages as targets for tumor immunotherapy.
Immunotherapy. 1:83–95. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guha M and Mackman N: LPS induction of
gene expression in human monocytes. Cell Signal. 13:85–94. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Alfano M, Graziano F, Genovese L and Poli
G: Macrophage polarization at the crossroad between HIV-1 infection
and cancer development. Arterioscler Thromb Vasc Biol.
33:1145–1152. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu XY, Miao ZF, Zhao TT, Wang ZN, Xu YY,
Gao J, Wu JH, You Y, Xu H and Xu HM: Milky spot macrophages
remodeled by gastric cancer cells promote peritoneal mesothelial
cell injury. Biochem Biophys Res Commun. 439:378–383. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tsukada T, Fushida S, Harada S, Yagi Y,
Kinoshita J, Oyama K, Tajima H, Fujita H, Ninomiya I, Fujimura T,
et al: The role of human peritoneal mesothelial cells in the
fibrosis and progression of gastric cancer. Int J Oncol.
41:476–482. 2012.PubMed/NCBI
|
|
42
|
Takaishi K, Komohara Y, Tashiro H, Ohtake
H, Nakagawa T, Katabuchi H and Takeya M: Involvement of
M2-polarized macrophages in the ascites from advanced epithelial
ovarian carcinoma in tumor progression via Stat3 activation. Cancer
Sci. 101:2128–2136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tang X, Mo C, Wang Y, Wei D and Xiao H:
Anti-tumour strategies aiming to target tumour-associated
macrophages. Immunology. 138:93–104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mantovani A, Sozzani S, Locati M, Allavena
P and Sica A: Macrophage polarization: Tumor-associated macrophages
as a paradigm for polarized M2 mononuclear phagocytes. Trends
Immunol. 23:549–555. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Platt N and Gordon S: Is the class A
macrophage scavenger receptor (SR-A) multifunctional? - The mouse's
tale. J Clin Invest. 108:649–654. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shigeoka M, Urakawa N, Nakamura T, Nishio
M, Watajima T, Kuroda D, Komori T, Kakeji Y, Semba S and Yokozaki
H: Tumor associated macrophage expressing CD204 is associated with
tumor aggressiveness of esophageal squamous cell carcinoma. Cancer
Sci. 104:1112–1119. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kurahara H, Shinchi H, Mataki Y, Maemura
K, Noma H, Kubo F, Sakoda M, Ueno S, Natsugoe S and Takao S:
Significance of M2-polarized tumor-associated macrophage in
pancreatic cancer. J Surg Res. 167:e211–e219. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yoshikawa K, Mitsunaga S, Kinoshita T,
Konishi M, Takahashi S, Gotohda N, Kato Y, Aizawa M and Ochiai A:
Impact of tumor-associated macrophages on invasive ductal carcinoma
of the pancreas head. Cancer Sci. 103:2012–2020. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hirayama S, Ishii G, Nagai K, Ono S,
Kojima M, Yamauchi C, Aokage K, Hishida T, Yoshida J, Suzuki K, et
al: Prognostic impact of CD204-positive macrophages in lung
squamous cell carcinoma: Possible contribution of Cd204-positive
macrophages to the tumor-promoting microenvironment. J Thorac
Oncol. 7:1790–1797. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhao Q, Qian Y, Li R, Tan B, Han H, Liu M,
Qian M and Du B: Norcantharidin facilitates LPS-mediated immune
responses by up-regulation of AKT/NF-κB signaling in macrophages.
PLoS One. 7:e449562012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu Y, Stewart KN, Bishop E, Marek CJ,
Kluth DC, Rees AJ and Wilson HM: Unique expression of suppressor of
cytokine signaling 3 is essential for classical macrophage
activation in rodents in vitro and in vivo. J Immunol.
180:6270–6278. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tamura S, Miki H, Okada K, Takeno A, Uji
K, Yoshida A, Suzuki R, Nakahira S, Egawa C, Nakata K, et al: Pilot
study of a combination of S-1 and paclitaxel for patients with
peritoneal metastasis from gastric cancer. Gastric Cancer.
13:101–108. 2010. View Article : Google Scholar : PubMed/NCBI
|
